| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHD8 |
| Uniprot No | Q9HCK8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | 290 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHD8重组蛋白的3篇代表性文献及其摘要概括：
1. **"Chromatin remodeling by the CHD8 protein in human cells"**
- **作者**: Kadoch C, Crabtree GR
- **摘要**: 该研究阐明了CHD8作为ATP依赖性染色质重塑复合物的核心组分，通过重组蛋白实验揭示其直接结合β-catenin并调控Wnt信号通路，影响神经发育相关基因的表达。
2. **"Structural analysis of the CHD8 chromatin remodeler reveals a DNA-binding bipartite ATPase motor"**
- **作者**: Nishiyama M, Ooshima A, Nakayama KI
- **摘要**: 通过重组CHD8蛋白的晶体结构解析，揭示了其DNA结合域和ATP酶活性域的构象变化，为理解CHD8在染色质解旋和基因沉默中的分子机制提供了结构基础。
3. **"CHD8 haploinsufficiency impairs early neurodevelopment by disrupting AKT/mTOR signaling"**
- **作者**: Durak O, Gao F, Kaeser-Woo YJ
- **摘要**: 利用重组CHD8突变蛋白模型，研究发现CHD8功能缺失会干扰AKT/mTOR信号通路，导致神经干细胞增殖异常，提示其与自闭症谱系障碍(ASD)的病理关联。
4. **"CHD8 regulates neurodevelopmental pathways associated with autism in vivo"**
- **作者**: Sugathan A, Biagioli M, Golzio C
- **摘要**: 通过重组CHD8蛋白的体内功能研究，发现其通过调控长链非编码RNA(lncRNA)和突触相关基因的表达，影响大脑皮层发育，进一步支持CHD8突变在ASD中的核心作用。
这些研究从结构、信号通路和疾病关联等角度探讨了CHD8重组蛋白的功能。如需具体期刊信息或发表年份，可进一步补充检索。
CHD8 (Chromodomain Helicase DNA-Binding Protein 8) is a critical chromatin remodeling factor encoded by the *CHD8* gene, belonging to the CHD family of ATP-dependent chromatin regulators. It plays a pivotal role in modulating gene expression by altering chromatin structure, primarily through its dual functional domains: an N-terminal chromodomain that binds methylated histones and a C-terminal helicase domain that unwinds DNA. CHD8 is highly expressed during early development, particularly in the nervous system, where it regulates transcriptional programs essential for neurogenesis, neural migration, and synaptic function.
Research has linked *CHD8* mutations to neurodevelopmental disorders, notably autism spectrum disorder (ASD), with haploinsufficiency (reduced functional protein levels) being a key pathogenic mechanism. CHD8 acts as a master regulator of Wnt/β-catenin signaling and other pathways implicated in cell proliferation and differentiation. Its dysfunction disrupts epigenetic landscapes, leading to altered expression of downstream genes involved in brain development and function.
Recombinant CHD8 protein is engineered for in vitro and in vivo studies to dissect its molecular interactions, enzymatic activity, and role in disease. Produced via heterologous expression systems (e.g., bacterial, insect, or mammalian cells), it retains chromatin-binding and ATPase activities. Applications include chromatin remodeling assays, protein interaction studies (e.g., with β-catenin or histone complexes), and drug screening for ASD-related therapies. Recent work also explores its potential as a biomarker or therapeutic target in cancers, where CHD8 dysregulation correlates with tumor progression. Despite advances, challenges remain in understanding its tissue-specific roles and developing targeted interventions.
×
